This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: stub-manual Compound WATCH-LIST MEDIUM

Pyrilutamide

Extended Research
Extended Research

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

Editor's verdict WATCH-LIST MEDIUM

Genuinely interesting — topical AR antagonists are the cleanest theoretical answer to MPB if they work (local effect, no systemic DHT change, no PFS risk in theory). Kintor's KX-826 Phase 2 MPB readout (2022) was mixed — primary endpoint not unambiguously met in some arms, hair count improvement was real but smaller than expected. Phase 3 ongoing. For a 20yo without MPB, nothing to evaluate. Flips to STRONG-CANDIDATE if Phase 3 reads cleanly positive AND a verified-COA source becomes available. Current research-chem supply is the same opaque channel as the rest of the gray-market hair compounds — identity, concentration, and purity not verifiable without LC-MS.

Research pass: stub-manual
Verdict change log
  • 2026-06-05 — Initial verdict WATCH-LIST. Track Kintor Phase 3 readout. (stub)

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…